Australia markets close in 3 hours 48 minutes
  • ALL ORDS

    7,758.10
    +29.60 (+0.38%)
     
  • ASX 200

    7,544.00
    +32.40 (+0.43%)
     
  • AUD/USD

    0.7072
    -0.0010 (-0.13%)
     
  • OIL

    76.02
    +0.14 (+0.18%)
     
  • GOLD

    1,917.00
    +0.70 (+0.04%)
     
  • BTC-AUD

    33,314.17
    -981.36 (-2.86%)
     
  • CMC Crypto 200

    537.13
    -8.19 (-1.50%)
     
  • AUD/EUR

    0.6487
    +0.0002 (+0.04%)
     
  • AUD/NZD

    1.0915
    -0.0015 (-0.14%)
     
  • NZX 50

    12,145.86
    -6.30 (-0.05%)
     
  • NASDAQ

    12,803.14
    +440.04 (+3.56%)
     
  • FTSE

    7,820.16
    +59.05 (+0.76%)
     
  • Dow Jones

    34,053.94
    -39.02 (-0.11%)
     
  • DAX

    15,509.19
    +328.45 (+2.16%)
     
  • Hang Seng

    21,958.36
    -113.82 (-0.52%)
     
  • NIKKEI 225

    27,580.06
    +178.01 (+0.65%)
     

Why Shares of Prometheus Biosciences Slumped This Week

Why Shares of Prometheus Biosciences Slumped This Week

Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.